Monthly Archives: June 2020

Enel Green Power has announced that it has been awarded 68 MW of new renewable capacity for two wind projects and 38.3 MW of nominal capacity deriving from the repowering of already-operational hydro plants in the second renewable auction launched by the state-owned energy service company GSE (Gestore Servizi Energetici) in Italy.

Specifically, the company participated in the 500 MW tender for new wind and solar projects and the 98.5 MW tender for renovations of renewable plants with a capacity exceeding 1 MW.

Regarding the new capacity, the two wind farms are located in Campania and Basilicata. The upgrading and useful life extension concern the three hydro plants already operating in the municipalities of Castiglione dei Pepoli (Bologna), Civitella in Val di Chiana (Arezzo) and Montecreto (Modena).

With this second award we confirm the commitment to invest in new renewable capacity in Italy, contributing to the challenging decarbonisation objectives of the Enel Group and the country,saidAntonio Cammisecra, CEO of Enel Green Power and Head of the Global Power Generation business line. Thanks to our development strategy, in 2019 the Groups installed capacity from renewables exceeded that from thermal sources globally, marking a further step forward towards the progressive replacement of fossil fuels with zero-emission ones.

The firm has stated that the construction of new capacity and the upgrading of existing plants in Italy are part of the wider commitment of the Enel Group to the growth of renewables and to decarbonisation which in our country foresees, in the 2020-2022 period, the development of new renewable capacity for around 700 MW and for which EGP has developed a pipeline of approximately 1.3 GW of opportunities that can start operating in the same period.

In the second auction conducted by GSE, wind won 406 MW of the 425 MW awarded in an undersubscribed auction 500 MW was on offer.

The primary reason for the undersubscription is Italys cumbersome and lengthy permitting process, stated WindEurope. Besides the challenges with permitting, the auction was also undersubscribed because repowering projects were not allowed to bid. This is significant. Italy has huge repowering potential: almost half of Italys installed wind fleet (10 GW) will reach the end of its operational life by 2030. The fact that repowering projects could not bid in the auction makes no sense.

Onshore wind accounted for the entire 406 MW of the 425 MW awarded in the most recent auction. The price range was from EUR 56/MWh to EUR 68.4/MWh. The weighted average was EUR 64.6/MWh.

Read more from the original source:

Enel Awarded 106.3 MW in Italy in GSE's Second Auction - Saurenergy

This is insane.

So declared former CIA Director Michael Hayden on hearing the news last week that President Donald Trump was considering pulling out of the Open Skies Treaty. In place since 1992, the treaty permits member states to conduct reconnaissance flights over each others territory to verify compliance and increase mutual trust. But Trump accused Russia of acting in bad faith and cheating on its commitments. Until they adhere, he announced, we will pull out. The presidents statement was the latest in a series of moves that have caused critics like Hayden to worry that he is dismantling arms control agreements that have kept the peace for decades.

Trumps record, however, suggests he sees little value in the existing regime. As a candidate, Trump railed against the Joint Comprehensive Plan of Action the 2015 deal to limit Irans nuclear program. As president, he withdrew from the deal, and the administration has kept up the rhetorical assault ever since. Just this month, Secretary of State Mike Pompeo called the Iran deal a failed attempt to appease terrorists.

The administration also withdrew from the Intermediate-Range Nuclear Forces (INF) Treaty President Reagans signature arms control agreement with the Soviet Union. This treaty was unique because it outlawed a whole class of weapons, rather than simply reducing numbers. But critics claimed that Russia was routinely violating the agreement and called on Trump to let it go. He did.

Finally, Trump is hinting that he will let the New START treaty expire next year, rather than negotiate a long-term extension with Moscow. Signed in 2010, New START placed limits on a range of missiles, bombers, and nuclear warheads. Arms control advocates are urging the administration to act quickly, but White House officials complain that the treaty doesnt include China and allows Russia to pursue a range of alternative technologies. Critics suspect the administration is simply looking for ways to let New START die, as it did with other arms control agreements.

Why does Trump reject these deals? Perhaps his ego makes him reluctant to enforce any agreement that doesnt have his name on it. Or maybe he just doesnt like the Obama administration. Trump got rid of the Iran nuclear deal, said a former State Department official, because it was Barack Obamas agreement.

There is probably truth to this. Trump has spent his whole career trying to be the center of attention and he has done little to hide his disdain for Obama. But these arguments cannot account for the longer-term trend in U.S. foreign policy. Recent administrations had mixed records on arms control. In some cases, they tried to strengthen existing agreements, but at other times they argued that it was time to move past Cold War regime. The George W. Bush administration famously abrogated the Anti-Ballistic Missile Treaty in 2002 despite intense criticism. Bush later signed a landmark nuclear-sharing agreement with India, which was not a member of the Nuclear Nonproliferation Treaty. This latter effort was particularly troubling for arms control advocates who believed that it was key to maintaining nuclear stability.

Obama also got crosswise with arms control advocates who expected a stronger commitment to disarmament. He started out by promising to take concrete steps towards a world without nuclear weapons, and he worked hard to complete the New START treaty with Russia. But Obama also shepherded a massive nuclear modernization program during his second term. His plans included life-extension programs for the current generation of aerial bombs and warheads, along with a new generation of cruise missiles, inter-continental ballistic missiles, bombers, and submarines. Obama did so to win support for New START from Senate Republicans, but his actions nonetheless struck observers as a betrayal of his earlier promises and left arms control advocates in dismay.

Seen in this light, Trumps actions are not such a radical break from the past. As with other issues, his outlandish rhetoric obscures areas of policy continuity. U.S. presidents since Dwight Eisenhower have publicly aspired to disarmament while simultaneously invested in a nuclear posture built around increasingly accurate and lethal weapons. The United States has consistently sought to stay ahead of all other nuclear-armed countries, friends and rivals alike, and has pushed for arms control treaties that lock in U.S. advantages. Ikes original Open Skies proposal, after all, promised an intelligence windfall at a time when Soviet security depended on keeping the Americans in the dark about its relative weakness. And if the Kremlin rejected a deal that promised transparency and peace, then Washington could claim a propaganda victory. In this and other cases, U.S. leaders favored arms control when they believed they could use it to achieve an American advantage. Trumps talk is unsubtle, but his commitment to maintaining nuclear superiority is not unusual.

What does all this suggest about the future of nuclear weapons in international politics? And what does it mean for the future of U.S. nuclear policy? The answer to both questions depends in large part on how we define arms control, a term whose meaning has divided scholars for decades. Broadly speaking, there are three schools of thought.

The first school envisions arms control as a path to disarmament. This appeals to common sense, given that arms control agreements seek to freeze the production of new weapons, limit the deployment of new forces, reduce the size of arsenals, and in some cases eliminate whole classes of weapons. Arms control agreements, seen in this respect, are piecemeal steps towards the ultimate goal of disarmament. It takes seriously Article VI of the Nuclear Nonproliferation Treaty, which calls for nuclear-armed states to make a good faith effort to eliminate their arsenals. Arms control is both a practical path towards that end, and a sign of good faith.

The second school envisions arms control as a path to strategic stability. This means reducing the incentives for states to engage in peacetime arms racing, and removing the temptation to strike first in a crisis. Arms control agreements that make it difficult for anyone to plausibly win a nuclear war serve both purposes. Stability will obtain when states agree to build and deploy only weapons that guarantee retaliation rather than promise victory. Public justification of the Anti-Ballistic Missile Treaty (1972) emphasized this logic. The reason for banning missile defenses was to demolish any fantasies that the superpowers could win a nuclear exchange in any meaningful sense.

The third school envisions arms control as a path to comparative advantage rather than collective security. States use arms control negotiations to achieve relative gains, either in terms of numbers or technology. For example, the Washington Naval Treaty (1922) obligated signatories to limit their naval tonnage according to an agreed ratio. Although advocates portrayed negotiations as an effort to avoid repeating the pre-World War I naval arms race, states used the treaty to lock in national advantages.

Similar motives lay just under the surface of Cold War arms control negotiations. Some observers celebrated the era of dtente in the 1970s as the time when superpowers sought to let the air out of their dangerous rivalry. New research, however, shows that successive U.S. administrations sought to use arms control diplomacy to maneuver the Soviet Union into a position of qualitative weakness. For the United States, success at the bargaining table would produce benefits that went beyond the nuclear balance. It would discourage Moscow from adventurism, and in so doing enhance the credibility of extended deterrence. In the event of war, it would allow the United States to reduce the costs in lives and treasure. And it would prompt Moscow to spend extravagantly on countermeasures, putting its economy under stress it could not bear.

Past presidents viewed arms control talks as a form of competition, not a forum for comity. In this sense, Trump is not so different from his predecessors, who also sought negotiations to maximize U.S. qualitative advantages. What makes Trump different is that he is dispensing with the pretext that arms control serves other purposes, or that strategic stability is intrinsically valuable. Trump sees himself as a dealmaker, not an institutionalist, and craves flexibility above all. Stability implies sacrificing flexibility on the altar of predictability, and that is something the president cannot abide.

Some observers applaud this approach. From their perspective, the devotion to stability leaves the United States vulnerable to authoritarian rivals who have no qualms about cheating on arms control agreements. In their view, adversaries will grow stronger as America sits idle, emboldened by Washingtons passive response to treaty violations and other provocations. Embracing stability even in the face of their deception is a recipe for disaster.

Trumps bluntness might also help the United States escape charges of hypocrisy. U.S. presidents since Eisenhower have pledged to work toward disarmament; they have also expanded and improved the U.S. arsenal. Observers naturally wonder if they mean what they say. Trumps straightforward appeal to the U.S. national interest might put some of those questions to rest, at least as long as he stays in office.

For the time being, the most important argument in support of Trumps approach is that it creates bargaining leverage. Negotiating strength, according to this logic, comes from a demonstrated willingness to walk away. Trump has repeatedly and loudly declared his willingness to do so, while holding out the prospect of renewing discussions later to achieve a better deal. Trumps flexibility means the door is never completely closed, so long as negotiating partners are ready to make concessions. This has been the case for Iran, North Korea, and now Russia. Were going to pull out, the president said last week, and theyre going to come back and want to make a deal.

The question, however, is whether this gamble for leverage will pay off. So far it has not. Iran has increased its stockpile of enriched uranium despite maximum pressure from the White House. Russia has continued to pursue what the Department of Defense calls a comprehensive modernization of its nuclear arsenal. China is also investing more in nuclear weapons, as the administration acknowledges. There have been no better deals with Iran or North Korea, and it is unclear why Russia would agree to one today. The administrations swagger has not caused U.S. adversaries to turn back the clock on enrichment or scuttle weapon-modernization plans. At best, the White House can point to North Koreas testing moratorium in place since 2017, but Pyongyang has recently intimated that it may start again.

One likely reason for these poor results is that an outspoken commitment to flexibility makes it hard to convince other states that the administration will honor its promises. Compelling adversaries to voluntarily reduce their capabilities is only likely to work if they are confident they will not be punished as a result. Trumps message that everything is always open to renegotiation implies that he is temperamentally unwilling to accept a long-term commitment to restraint. Under these conditions, they have no reason to accept meaningful limits.

Trumps unapologetic embrace of nationalism also makes it hard to explain why arms control agreements are mutually beneficial. The White House has repeatedly argued, for example, that any future START treaty must include China. But by casting its arguments only in terms of U.S. gains, it is probably impossible to convince Beijing to cap its growing nuclear stockpile. As Caitlin Talmadge recently pointed out, Chinese leaders will almost certainly be wary of such an overture unless the administration can talk credibly about Chinese interests.

The irony is that Trumps nationalist bluster works against the national interest. The United States has used arms control for a number of purposes over the years, including the pursuit of its own parochial goals. The process has required U.S. concessions, but the long-term results have been overwhelmingly positive: The number of nuclear powers has stayed the same, the number of nuclear warheads has gone down, and the U.S. qualitative lead has increased. By publicly eschewing the pretense of mutual gains, Trump is putting U.S. gains at risk.

Joshua Rovner is associate professor in the School of International Service at American University.

Image: U.S. Air Force (Photo by Charles J. Haymond)

See the rest here:

Has the United States Abandoned Arms Control? - War on the Rocks

The Cracow Gold Mine is on track to produce 82,500 87,500 ounces of gold in the 2020 financial year and generate net mine cash flow of $84 to $89 million.

() has entered into a binding agreement with () to acquire the Cracow Gold Mine in Queensland.

Cracow is an established, high grade, low-cost underground gold mining operation and processing facility operating continuously since 2004, producing more than 1.4 million ounces over its life, with a consistent track record of profitability and reserve replacement.

The mine is on track to produce 82,500 87,500 ounces of gold in the 2020 financial year and generate net mine cash flow of $84 to $89 million.

Aeris has agreed to pay Evolution $60 million in cash upon closing of the transaction, a deferred payment of $15 million on June 30, 2022 plus a 10% net value royalty from July 1, 2022 to June 30, 2027, capped at $50 million.

Completion of the transaction is expected to occur on June 30, 2020.

Aeris executive chairman Andre Labuschagne said: This is a truly transformational transaction for Aeris and will be immediately accretive in value.

The acquisition provides us with asset and commodity diversity, strong cashflow generation and high value synergies.

Cracow will be a perfect fit for the unique skill set of our management team, who have a track record of extracting value and life extensions, as demonstrated at the Tritton mine, and previously with Norton Gold Fields at the Paddington gold mine. Our immediate focus will be on transitioning Cracow into the Aeris culture and aggressively investing in the mine life extension opportunities we have identified.

Labuschagne added: Aeris inherits a well-run, proven operation which has been a consistent performer for Evolution.

Importantly for us, there is a strong operating team in place that has a culture of continuous improvement.

We are confident that Cracow management and the workforce will fit well with Aeris own culture and the renewed focus to reinvesting in mine life extensions which Aeris will bring.

Aeris intends to fund the transaction through a fully underwritten $40 million equity raising and a $30 million acquisition bridge debt facility.

A new $15 million guarantee facility has also been secured to provide for the replacement of financial assurances relating to the mine and will be provided by SPOV (Special Portfolio Opportunity V), a subsidiary of a fund managed by PAG.

The equity raising will be conducted via a fully underwritten institutional placement and an underwritten 2.02 for 1 pro-rata accelerated renounceable entitlement offer.

Aeris has already secured commitments from its three largest shareholders, representing about 60% of the register to commit to participating in the equity raising, subject to a maximum holding of 19.99% at completion.

The Cracow Gold Mine is about 500 kilometres north-west of Brisbane in a highly endowed goldfield with gold mineralisation hosted in steeply dipping structurally controlled low sulphidation epithermal veins.

The underground mine is accessed through a single surface decline with ore primarily mined via open stoping through a modified Avoca mining sequence.

Cracow has a strong track record of reserve and resource replacement and Aeris plans to aggressively invest in brownfield and greenfield exploration with the aim of growing the resource base to extend mine life.

Multiple near term opportunities for resource conversion have been identified with about $13 million budgeted over the next two years for exploration, with key priorities including both underground near-mine extensions (e.g. Killarney) as well as nearby open-pit deposits (e.g. the Golden Plateau and Roses Pride).

Extracting value through integration efficiencies will also be a key driver of Aeris immediate plan with about $4 million of targeted annual cost synergies as well as the potential for utilising Aeris existing carried forward tax losses ($256 million at June 30, 2019).

Over the two year period to June 30, 2022, Aeris expects Cracow to generate more than $100 million of net mine cash flows at the current gold price, with pro forma Aeris group EBITDA of $272 million to $282 million and pro forma group net mine cash flows of $137 million to $155 million.

This significant cashflow will provide for both investment in life of mine extension projects at Cracow and Tritton as well as to also continue deleveraging Aeris balance sheet.

To protect the very significant near term positive cashflows from Cracow, Aeris intends to enter a prudent gold hedging program, with an initial focus on the first 12 months.

See original here:

Aeris Resources to acquire producing gold mine from Evolution in transformational move - Proactive Investors Australia

CAMBRIDGE, Mass., June 4, 2020 /PRNewswire/ -- Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces the completion of an extension to its Series B financing led by Columbus Venture Partners.

AX-158 is a first-in-class, oral small molecule, immunomodulating agent in development for the treatment of autoimmune diseases. AX-158 employs a novel mechanism of action that selectively modulates, or adjusts, T cell responses that play a critical role in immune system function. Proceeds from the financing will be used to support activities for a planned Q4 2020 filing of a Clinical Trial Application (CTA) with the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for AX-158.

"We are pleased to welcome Columbus Venture Partners as a new investor," said Joseph Lobacki, Chief Executive Officer of Artax Biopharma. "The support of Columbus Venture Partners is a testament to the transformative potential of our science, which has the potential to address autoimmune disease without causing immunosuppression."

Javier Garca, Founder and Partner with Columbus Venture Partners, stated, "Columbus Venture Partners is pleased to have led the extension to this round of financing. We believe Artax's highly experienced leadership team is well positioned to deliver on a truly innovative therapeutic program."

About ImmunomodulationA healthy immune system eliminates harmful foreign pathogens, while being tolerant of self-tissues and organs. When the immune system malfunctions, cells (T Cells) attack self-tissues and organs, causing autoimmune disease. Current autoimmune disease therapies suppress the immune system, helping to minimize these self-attacks, but also raise susceptibility to harmful foreign pathogens. Immunomodulation, the process in which the immune system reduces self-attacks while properly reacting to fight foreign pathogens, holds great potential for autoimmune disease therapies.

About Artax-158AX-158 is a first-in-class, oral small molecule, preclinical immunomodulating agent in development for the treatment of autoimmune diseases. AX-158 employs a novel mechanism of action that selectively modulates, or adjusts, T cell responses that play a critical role in immune system function. By selectively inhibiting Nck, a protein, AX-158 selectively modulates self-directed T Cell activation which is a cause of autoimmune disease. Importantly, data suggests that AX-158 is not immunosuppressive and does not impact the immune system's ability to mount a strong response to foreign pathogens and infections. Further, AX-158's ability to modulate T cell responses allows the possibility to broadly target several autoimmune diseases, therefore potentially transforming autoimmune disease treatment.

About Artax BiopharmaArtax Biopharma is a biotechnology company transforming autoimmune disease treatment. Artax is a life science industry leader in autoimmune disease immunomodulation science, developing an innovative small molecule approach to treat autoimmune disease that modulates the immune system to both treat autoimmune disease and allow the body to fight foreign pathogens. The company is examining a first-in-class oral immunomodulating agent as a new way to treat multiple autoimmune diseases without causing the immune suppression commonly associated with currently available autoimmune disease therapies. For more information, please visit http://www.artaxbiopharma.com.

View original content:http://www.prnewswire.com/news-releases/artax-biopharma-announces-series-b-financing-extension-to-advance-first-in-class-autoimmune-disease-therapy-301070326.html

SOURCE Artax Biopharma

See original here:

Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy - P&T Community

Motorists due to renew their photocard driving licence have been granted a seven-month extension by the DVLA in the wake of the coronavirus crisis.

The Driver and Vehicle Licensing Agency has said that anyone whose licence is due to expire between February 1 and August 31, 2020 will receive an automatic extension. A similar extension has been put in place by the Driver and Vehicle Agency in Northern Ireland.

The move is intended to allow drivers to continue to make necessary journeys without having to obtain a new photograph as part of the renewal process.

It comes due to the introduction of a new EU Driving Licence Directive which looks to address difficulties caused by the coronavirus outbreak. The directive says: In order to ensure the smooth functioning of the internal market, a high level of transport safety, to provide legal certainty, and to avoid potential market disruption, it is necessary to adopt temporary provisions extending the validity of those certificates, licences or authorisations that would expire between 1 March 2020 and 31 August 2020 and ensuring that they remain valid during a reasonable period of time during and after the COVID-19 outbreak."

DVLA chief executive Julie Lennard said: This extension will make it easier for drivers who need to update their photocard licence with a new photograph. This means as long as they have a valid licence, drivers will be able to continue to make essential journeys.

The extension is automatic so drivers do not need to do anything and will be sent a reminder to renew their photocard before the extension ends.

The change comes into force from June 4, 2020 and only applies to photocard licence renewal. Anyone whose entitlement to drive is due to expire, for example due to their age, and who wishes to continue to hold a valid licence will need to renew this entitlement in the normal way.

Normally drivers are required to renew their photocard licence every 10 years, and bus and lorry drivers every five years. Driving entitlement on a car (Group 1) licence generally remains in force until the driver reaches 70, unless revoked or surrendered. At aged 70 the driver must renew their entitlement to drive every three years if they wish to continue to hold a valid licence.

More here:

Drivers granted automatic licence renewal extension - Farming Life

The market research report published by QYResearch is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global COVID-19 Impact on Melatonine market. It informs readers about key trends and opportunities in the global COVID-19 Impact on Melatonine market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global COVID-19 Impact on Melatonine market.

Key companies operating in the global COVID-19 Impact on Melatonine market include , Life Extension, Pharmavite, NOW Foods, Source Naturals, BY-HEALTH, GNC, Centrum, Jamieson Vitamins, Nutraceutical Corporation, Haviland Enterprises Inc., Pharma Resources International LLC, AIE Pharmaceuticals, Gemini Pharmaceuticals, Spectrum Chemical Mfg. Corp., Nutritional Supplement Manufacturers Inc., Van Wankum Ingredients, Action Labs Inc., Softgel Nutraceuticals, Norquay Technology Inc., Arnet Pharmaceutical, Twinlab Corp., Superior Supplement Manufacturing, The Chemical Co. Melatonine

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1711659/covid-19-impact-on-global-melatonine-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global COVID-19 Impact on Melatonine market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global COVID-19 Impact on Melatonine Market Segment By Type:

, Capsule, Pills, Liquid Melatonine

Global COVID-19 Impact on Melatonine Market Segment By Application:

, Hospital, Clinic, Household, Other

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global COVID-19 Impact on Melatonine market.

Key companies operating in the global COVID-19 Impact on Melatonine market include , Life Extension, Pharmavite, NOW Foods, Source Naturals, BY-HEALTH, GNC, Centrum, Jamieson Vitamins, Nutraceutical Corporation, Haviland Enterprises Inc., Pharma Resources International LLC, AIE Pharmaceuticals, Gemini Pharmaceuticals, Spectrum Chemical Mfg. Corp., Nutritional Supplement Manufacturers Inc., Van Wankum Ingredients, Action Labs Inc., Softgel Nutraceuticals, Norquay Technology Inc., Arnet Pharmaceutical, Twinlab Corp., Superior Supplement Manufacturing, The Chemical Co. Melatonine

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1711659/covid-19-impact-on-global-melatonine-market

TOC

1 Study Coverage1.1 Melatonine Product Introduction1.2 Market Segments1.3 Key Melatonine Manufacturers Covered: Ranking by Revenue1.4 Market by Type 1.4.1 Global Melatonine Market Size Growth Rate by Type 1.4.2 Capsule 1.4.3 Pills 1.4.4 Liquid1.5 Market by Application 1.5.1 Global Melatonine Market Size Growth Rate by Application 1.5.2 Hospital 1.5.3 Clinic 1.5.4 Household 1.5.5 Other1.6 Coronavirus Disease 2019 (Covid-19): Melatonine Industry Impact 1.6.1 How the Covid-19 is Affecting the Melatonine Industry 1.6.1.1 Melatonine Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Melatonine Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Melatonine Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global Melatonine Market Size Estimates and Forecasts 2.1.1 Global Melatonine Revenue 2015-2026 2.1.2 Global Melatonine Sales 2015-20262.2 Melatonine Market Size by Region: 2020 Versus 2026 2.2.1 Global Melatonine Retrospective Market Scenario in Sales by Region: 2015-2020 2.2.2 Global Melatonine Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Melatonine Competitor Landscape by Players3.1 Melatonine Sales by Manufacturers 3.1.1 Melatonine Sales by Manufacturers (2015-2020) 3.1.2 Melatonine Sales Market Share by Manufacturers (2015-2020)3.2 Melatonine Revenue by Manufacturers 3.2.1 Melatonine Revenue by Manufacturers (2015-2020) 3.2.2 Melatonine Revenue Share by Manufacturers (2015-2020) 3.2.3 Global Melatonine Market Concentration Ratio (CR5 and HHI) (2015-2020) 3.2.4 Global Top 10 and Top 5 Companies by Melatonine Revenue in 2019 3.2.5 Global Melatonine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Melatonine Price by Manufacturers3.4 Melatonine Manufacturing Base Distribution, Product Types 3.4.1 Melatonine Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Melatonine Product Type 3.4.3 Date of International Manufacturers Enter into Melatonine Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Melatonine Market Size by Type (2015-2020) 4.1.1 Global Melatonine Sales by Type (2015-2020) 4.1.2 Global Melatonine Revenue by Type (2015-2020) 4.1.3 Melatonine Average Selling Price (ASP) by Type (2015-2026)4.2 Global Melatonine Market Size Forecast by Type (2021-2026) 4.2.1 Global Melatonine Sales Forecast by Type (2021-2026) 4.2.2 Global Melatonine Revenue Forecast by Type (2021-2026) 4.2.3 Melatonine Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Melatonine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global Melatonine Market Size by Application (2015-2020) 5.1.1 Global Melatonine Sales by Application (2015-2020) 5.1.2 Global Melatonine Revenue by Application (2015-2020) 5.1.3 Melatonine Price by Application (2015-2020)5.2 Melatonine Market Size Forecast by Application (2021-2026) 5.2.1 Global Melatonine Sales Forecast by Application (2021-2026) 5.2.2 Global Melatonine Revenue Forecast by Application (2021-2026) 5.2.3 Global Melatonine Price Forecast by Application (2021-2026) 6 North America6.1 North America Melatonine by Country 6.1.1 North America Melatonine Sales by Country 6.1.2 North America Melatonine Revenue by Country 6.1.3 U.S. 6.1.4 Canada6.2 North America Melatonine Market Facts & Figures by Type6.3 North America Melatonine Market Facts & Figures by Application 7 Europe7.1 Europe Melatonine by Country 7.1.1 Europe Melatonine Sales by Country 7.1.2 Europe Melatonine Revenue by Country 7.1.3 Germany 7.1.4 France 7.1.5 U.K. 7.1.6 Italy 7.1.7 Russia7.2 Europe Melatonine Market Facts & Figures by Type7.3 Europe Melatonine Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific Melatonine by Region 8.1.1 Asia Pacific Melatonine Sales by Region 8.1.2 Asia Pacific Melatonine Revenue by Region 8.1.3 China 8.1.4 Japan 8.1.5 South Korea 8.1.6 India 8.1.7 Australia 8.1.8 Taiwan 8.1.9 Indonesia 8.1.10 Thailand 8.1.11 Malaysia 8.1.12 Philippines 8.1.13 Vietnam8.2 Asia Pacific Melatonine Market Facts & Figures by Type8.3 Asia Pacific Melatonine Market Facts & Figures by Application 9 Latin America9.1 Latin America Melatonine by Country 9.1.1 Latin America Melatonine Sales by Country 9.1.2 Latin America Melatonine Revenue by Country 9.1.3 Mexico 9.1.4 Brazil 9.1.5 Argentina9.2 Central & South America Melatonine Market Facts & Figures by Type9.3 Central & South America Melatonine Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa Melatonine by Country 10.1.1 Middle East and Africa Melatonine Sales by Country 10.1.2 Middle East and Africa Melatonine Revenue by Country 10.1.3 Turkey 10.1.4 Saudi Arabia 10.1.5 UAE10.2 Middle East and Africa Melatonine Market Facts & Figures by Type10.3 Middle East and Africa Melatonine Market Facts & Figures by Application 11 Company Profiles11.1 Life Extension 11.1.1 Life Extension Corporation Information 11.1.2 Life Extension Description, Business Overview and Total Revenue 11.1.3 Life Extension Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Life Extension Melatonine Products Offered 11.1.5 Life Extension Recent Development11.2 Pharmavite 11.2.1 Pharmavite Corporation Information 11.2.2 Pharmavite Description, Business Overview and Total Revenue 11.2.3 Pharmavite Sales, Revenue and Gross Margin (2015-2020) 11.2.4 Pharmavite Melatonine Products Offered 11.2.5 Pharmavite Recent Development11.3 NOW Foods 11.3.1 NOW Foods Corporation Information 11.3.2 NOW Foods Description, Business Overview and Total Revenue 11.3.3 NOW Foods Sales, Revenue and Gross Margin (2015-2020) 11.3.4 NOW Foods Melatonine Products Offered 11.3.5 NOW Foods Recent Development11.4 Source Naturals 11.4.1 Source Naturals Corporation Information 11.4.2 Source Naturals Description, Business Overview and Total Revenue 11.4.3 Source Naturals Sales, Revenue and Gross Margin (2015-2020) 11.4.4 Source Naturals Melatonine Products Offered 11.4.5 Source Naturals Recent Development11.5 BY-HEALTH 11.5.1 BY-HEALTH Corporation Information 11.5.2 BY-HEALTH Description, Business Overview and Total Revenue 11.5.3 BY-HEALTH Sales, Revenue and Gross Margin (2015-2020) 11.5.4 BY-HEALTH Melatonine Products Offered 11.5.5 BY-HEALTH Recent Development11.6 GNC 11.6.1 GNC Corporation Information 11.6.2 GNC Description, Business Overview and Total Revenue 11.6.3 GNC Sales, Revenue and Gross Margin (2015-2020) 11.6.4 GNC Melatonine Products Offered 11.6.5 GNC Recent Development11.7 Centrum 11.7.1 Centrum Corporation Information 11.7.2 Centrum Description, Business Overview and Total Revenue 11.7.3 Centrum Sales, Revenue and Gross Margin (2015-2020) 11.7.4 Centrum Melatonine Products Offered 11.7.5 Centrum Recent Development11.8 Jamieson Vitamins 11.8.1 Jamieson Vitamins Corporation Information 11.8.2 Jamieson Vitamins Description, Business Overview and Total Revenue 11.8.3 Jamieson Vitamins Sales, Revenue and Gross Margin (2015-2020) 11.8.4 Jamieson Vitamins Melatonine Products Offered 11.8.5 Jamieson Vitamins Recent Development11.9 Nutraceutical Corporation 11.9.1 Nutraceutical Corporation Corporation Information 11.9.2 Nutraceutical Corporation Description, Business Overview and Total Revenue 11.9.3 Nutraceutical Corporation Sales, Revenue and Gross Margin (2015-2020) 11.9.4 Nutraceutical Corporation Melatonine Products Offered 11.9.5 Nutraceutical Corporation Recent Development11.10 Haviland Enterprises Inc. 11.10.1 Haviland Enterprises Inc. Corporation Information 11.10.2 Haviland Enterprises Inc. Description, Business Overview and Total Revenue 11.10.3 Haviland Enterprises Inc. Sales, Revenue and Gross Margin (2015-2020) 11.10.4 Haviland Enterprises Inc. Melatonine Products Offered 11.10.5 Haviland Enterprises Inc. Recent Development11.1 Life Extension 11.1.1 Life Extension Corporation Information 11.1.2 Life Extension Description, Business Overview and Total Revenue 11.1.3 Life Extension Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Life Extension Melatonine Products Offered 11.1.5 Life Extension Recent Development11.12 AIE Pharmaceuticals 11.12.1 AIE Pharmaceuticals Corporation Information 11.12.2 AIE Pharmaceuticals Description, Business Overview and Total Revenue 11.12.3 AIE Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020) 11.12.4 AIE Pharmaceuticals Products Offered 11.12.5 AIE Pharmaceuticals Recent Development11.13 Gemini Pharmaceuticals 11.13.1 Gemini Pharmaceuticals Corporation Information 11.13.2 Gemini Pharmaceuticals Description, Business Overview and Total Revenue 11.13.3 Gemini Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020) 11.13.4 Gemini Pharmaceuticals Products Offered 11.13.5 Gemini Pharmaceuticals Recent Development11.14 Spectrum Chemical Mfg. Corp. 11.14.1 Spectrum Chemical Mfg. Corp. Corporation Information 11.14.2 Spectrum Chemical Mfg. Corp. Description, Business Overview and Total Revenue 11.14.3 Spectrum Chemical Mfg. Corp. Sales, Revenue and Gross Margin (2015-2020) 11.14.4 Spectrum Chemical Mfg. Corp. Products Offered 11.14.5 Spectrum Chemical Mfg. Corp. Recent Development11.15 Nutritional Supplement Manufacturers Inc. 11.15.1 Nutritional Supplement Manufacturers Inc. Corporation Information 11.15.2 Nutritional Supplement Manufacturers Inc. Description, Business Overview and Total Revenue 11.15.3 Nutritional Supplement Manufacturers Inc. Sales, Revenue and Gross Margin (2015-2020) 11.15.4 Nutritional Supplement Manufacturers Inc. Products Offered 11.15.5 Nutritional Supplement Manufacturers Inc. Recent Development11.16 Van Wankum Ingredients 11.16.1 Van Wankum Ingredients Corporation Information 11.16.2 Van Wankum Ingredients Description, Business Overview and Total Revenue 11.16.3 Van Wankum Ingredients Sales, Revenue and Gross Margin (2015-2020) 11.16.4 Van Wankum Ingredients Products Offered 11.16.5 Van Wankum Ingredients Recent Development11.17 Action Labs Inc. 11.17.1 Action Labs Inc. Corporation Information 11.17.2 Action Labs Inc. Description, Business Overview and Total Revenue 11.17.3 Action Labs Inc. Sales, Revenue and Gross Margin (2015-2020) 11.17.4 Action Labs Inc. Products Offered 11.17.5 Action Labs Inc. Recent Development11.18 Softgel Nutraceuticals 11.18.1 Softgel Nutraceuticals Corporation Information 11.18.2 Softgel Nutraceuticals Description, Business Overview and Total Revenue 11.18.3 Softgel Nutraceuticals Sales, Revenue and Gross Margin (2015-2020) 11.18.4 Softgel Nutraceuticals Products Offered 11.18.5 Softgel Nutraceuticals Recent Development11.19 Norquay Technology Inc. 11.19.1 Norquay Technology Inc. Corporation Information 11.19.2 Norquay Technology Inc. Description, Business Overview and Total Revenue 11.19.3 Norquay Technology Inc. Sales, Revenue and Gross Margin (2015-2020) 11.19.4 Norquay Technology Inc. Products Offered 11.19.5 Norquay Technology Inc. Recent Development11.20 Arnet Pharmaceutical 11.20.1 Arnet Pharmaceutical Corporation Information 11.20.2 Arnet Pharmaceutical Description, Business Overview and Total Revenue 11.20.3 Arnet Pharmaceutical Sales, Revenue and Gross Margin (2015-2020) 11.20.4 Arnet Pharmaceutical Products Offered 11.20.5 Arnet Pharmaceutical Recent Development11.21 Twinlab Corp. 11.21.1 Twinlab Corp. Corporation Information 11.21.2 Twinlab Corp. Description, Business Overview and Total Revenue 11.21.3 Twinlab Corp. Sales, Revenue and Gross Margin (2015-2020) 11.21.4 Twinlab Corp. Products Offered 11.21.5 Twinlab Corp. Recent Development11.22 Superior Supplement Manufacturing 11.22.1 Superior Supplement Manufacturing Corporation Information 11.22.2 Superior Supplement Manufacturing Description, Business Overview and Total Revenue 11.22.3 Superior Supplement Manufacturing Sales, Revenue and Gross Margin (2015-2020) 11.22.4 Superior Supplement Manufacturing Products Offered 11.22.5 Superior Supplement Manufacturing Recent Development11.23 The Chemical Co. 11.23.1 The Chemical Co. Corporation Information 11.23.2 The Chemical Co. Description, Business Overview and Total Revenue 11.23.3 The Chemical Co. Sales, Revenue and Gross Margin (2015-2020) 11.23.4 The Chemical Co. Products Offered 11.23.5 The Chemical Co. Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 Melatonine Market Estimates and Projections by Region 12.1.1 Global Melatonine Sales Forecast by Regions 2021-2026 12.1.2 Global Melatonine Revenue Forecast by Regions 2021-202612.2 North America Melatonine Market Size Forecast (2021-2026) 12.2.1 North America: Melatonine Sales Forecast (2021-2026) 12.2.2 North America: Melatonine Revenue Forecast (2021-2026) 12.2.3 North America: Melatonine Market Size Forecast by Country (2021-2026)12.3 Europe Melatonine Market Size Forecast (2021-2026) 12.3.1 Europe: Melatonine Sales Forecast (2021-2026) 12.3.2 Europe: Melatonine Revenue Forecast (2021-2026) 12.3.3 Europe: Melatonine Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Melatonine Market Size Forecast (2021-2026) 12.4.1 Asia Pacific: Melatonine Sales Forecast (2021-2026) 12.4.2 Asia Pacific: Melatonine Revenue Forecast (2021-2026) 12.4.3 Asia Pacific: Melatonine Market Size Forecast by Region (2021-2026)12.5 Latin America Melatonine Market Size Forecast (2021-2026) 12.5.1 Latin America: Melatonine Sales Forecast (2021-2026) 12.5.2 Latin America: Melatonine Revenue Forecast (2021-2026) 12.5.3 Latin America: Melatonine Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Melatonine Market Size Forecast (2021-2026) 12.6.1 Middle East and Africa: Melatonine Sales Forecast (2021-2026) 12.6.2 Middle East and Africa: Melatonine Revenue Forecast (2021-2026) 12.6.3 Middle East and Africa: Melatonine Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Melatonine Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Melatonine Customers14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source16.2 Author Details16.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

The rest is here:

COVID-19 Impact on Melatonine Market Research Report: Probable Key Development To Be Observed Market States And Outlook Across By 2026 - News Distinct

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Reishi Mushroom Supplements market. It informs readers about key trends and opportunities in the global Reishi Mushroom Supplements market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Reishi Mushroom Supplements market.

Key companies operating in the global Reishi Mushroom Supplements market include , Natures Way Reishi, Solaray Reishi Mushroom, Life Extension Reishi Extract, Host Defense Reishi, Terrasoul Superfoods, Swanson Reishi Mushroom, Aloha Medicinals, Mushroom Science, Planetary Herbals Reishi Mushroom Supplements

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1733074/global-reishi-mushroom-supplements-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Reishi Mushroom Supplements market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Reishi Mushroom Supplements Market Segment By Type:

, Organic Reishi Mushroom Supplements, Inorganic Reishi Mushroom Supplements Reishi Mushroom Supplements

Global Reishi Mushroom Supplements Market Segment By Application:

, Online Sales, Offline Sales

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Reishi Mushroom Supplements market.

Key companies operating in the global Reishi Mushroom Supplements market include , Natures Way Reishi, Solaray Reishi Mushroom, Life Extension Reishi Extract, Host Defense Reishi, Terrasoul Superfoods, Swanson Reishi Mushroom, Aloha Medicinals, Mushroom Science, Planetary Herbals Reishi Mushroom Supplements

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1733074/global-reishi-mushroom-supplements-market

TOC

1 Study Coverage1.1 Reishi Mushroom Supplements Product Introduction1.2 Market Segments1.3 Key Reishi Mushroom Supplements Manufacturers Covered: Ranking by Revenue1.4 Market by Type 1.4.1 Global Reishi Mushroom Supplements Market Size Growth Rate by Type 1.4.2 Organic Reishi Mushroom Supplements 1.4.3 Inorganic Reishi Mushroom Supplements1.5 Market by Application 1.5.1 Global Reishi Mushroom Supplements Market Size Growth Rate by Application 1.5.2 Online Sales 1.5.3 Offline Sales1.6 Coronavirus Disease 2019 (Covid-19): Reishi Mushroom Supplements Industry Impact 1.6.1 How the Covid-19 is Affecting the Reishi Mushroom Supplements Industry 1.6.1.1 Reishi Mushroom Supplements Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Reishi Mushroom Supplements Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Reishi Mushroom Supplements Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global Reishi Mushroom Supplements Market Size Estimates and Forecasts 2.1.1 Global Reishi Mushroom Supplements Revenue 2015-2026 2.1.2 Global Reishi Mushroom Supplements Sales 2015-20262.2 Reishi Mushroom Supplements Market Size by Region: 2020 Versus 2026 2.2.1 Global Reishi Mushroom Supplements Retrospective Market Scenario in Sales by Region: 2015-2020 2.2.2 Global Reishi Mushroom Supplements Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Reishi Mushroom Supplements Competitor Landscape by Players3.1 Reishi Mushroom Supplements Sales by Manufacturers 3.1.1 Reishi Mushroom Supplements Sales by Manufacturers (2015-2020) 3.1.2 Reishi Mushroom Supplements Sales Market Share by Manufacturers (2015-2020)3.2 Reishi Mushroom Supplements Revenue by Manufacturers 3.2.1 Reishi Mushroom Supplements Revenue by Manufacturers (2015-2020) 3.2.2 Reishi Mushroom Supplements Revenue Share by Manufacturers (2015-2020) 3.2.3 Global Reishi Mushroom Supplements Market Concentration Ratio (CR5 and HHI) (2015-2020) 3.2.4 Global Top 10 and Top 5 Companies by Reishi Mushroom Supplements Revenue in 2019 3.2.5 Global Reishi Mushroom Supplements Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Reishi Mushroom Supplements Price by Manufacturers3.4 Reishi Mushroom Supplements Manufacturing Base Distribution, Product Types 3.4.1 Reishi Mushroom Supplements Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Reishi Mushroom Supplements Product Type 3.4.3 Date of International Manufacturers Enter into Reishi Mushroom Supplements Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Reishi Mushroom Supplements Market Size by Type (2015-2020) 4.1.1 Global Reishi Mushroom Supplements Sales by Type (2015-2020) 4.1.2 Global Reishi Mushroom Supplements Revenue by Type (2015-2020) 4.1.3 Reishi Mushroom Supplements Average Selling Price (ASP) by Type (2015-2026)4.2 Global Reishi Mushroom Supplements Market Size Forecast by Type (2021-2026) 4.2.1 Global Reishi Mushroom Supplements Sales Forecast by Type (2021-2026) 4.2.2 Global Reishi Mushroom Supplements Revenue Forecast by Type (2021-2026) 4.2.3 Reishi Mushroom Supplements Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Reishi Mushroom Supplements Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global Reishi Mushroom Supplements Market Size by Application (2015-2020) 5.1.1 Global Reishi Mushroom Supplements Sales by Application (2015-2020) 5.1.2 Global Reishi Mushroom Supplements Revenue by Application (2015-2020) 5.1.3 Reishi Mushroom Supplements Price by Application (2015-2020)5.2 Reishi Mushroom Supplements Market Size Forecast by Application (2021-2026) 5.2.1 Global Reishi Mushroom Supplements Sales Forecast by Application (2021-2026) 5.2.2 Global Reishi Mushroom Supplements Revenue Forecast by Application (2021-2026) 5.2.3 Global Reishi Mushroom Supplements Price Forecast by Application (2021-2026) 6 North America6.1 North America Reishi Mushroom Supplements by Country 6.1.1 North America Reishi Mushroom Supplements Sales by Country 6.1.2 North America Reishi Mushroom Supplements Revenue by Country 6.1.3 U.S. 6.1.4 Canada6.2 North America Reishi Mushroom Supplements Market Facts & Figures by Type6.3 North America Reishi Mushroom Supplements Market Facts & Figures by Application 7 Europe7.1 Europe Reishi Mushroom Supplements by Country 7.1.1 Europe Reishi Mushroom Supplements Sales by Country 7.1.2 Europe Reishi Mushroom Supplements Revenue by Country 7.1.3 Germany 7.1.4 France 7.1.5 U.K. 7.1.6 Italy 7.1.7 Russia7.2 Europe Reishi Mushroom Supplements Market Facts & Figures by Type7.3 Europe Reishi Mushroom Supplements Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific Reishi Mushroom Supplements by Region 8.1.1 Asia Pacific Reishi Mushroom Supplements Sales by Region 8.1.2 Asia Pacific Reishi Mushroom Supplements Revenue by Region 8.1.3 China 8.1.4 Japan 8.1.5 South Korea 8.1.6 India 8.1.7 Australia 8.1.8 Taiwan 8.1.9 Indonesia 8.1.10 Thailand 8.1.11 Malaysia 8.1.12 Philippines 8.1.13 Vietnam8.2 Asia Pacific Reishi Mushroom Supplements Market Facts & Figures by Type8.3 Asia Pacific Reishi Mushroom Supplements Market Facts & Figures by Application 9 Latin America9.1 Latin America Reishi Mushroom Supplements by Country 9.1.1 Latin America Reishi Mushroom Supplements Sales by Country 9.1.2 Latin America Reishi Mushroom Supplements Revenue by Country 9.1.3 Mexico 9.1.4 Brazil 9.1.5 Argentina9.2 Central & South America Reishi Mushroom Supplements Market Facts & Figures by Type9.3 Central & South America Reishi Mushroom Supplements Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa Reishi Mushroom Supplements by Country 10.1.1 Middle East and Africa Reishi Mushroom Supplements Sales by Country 10.1.2 Middle East and Africa Reishi Mushroom Supplements Revenue by Country 10.1.3 Turkey 10.1.4 Saudi Arabia 10.1.5 U.A.E10.2 Middle East and Africa Reishi Mushroom Supplements Market Facts & Figures by Type10.3 Middle East and Africa Reishi Mushroom Supplements Market Facts & Figures by Application 11 Company Profiles11.1 Natures Way Reishi 11.1.1 Natures Way Reishi Corporation Information 11.1.2 Natures Way Reishi Description, Business Overview and Total Revenue 11.1.3 Natures Way Reishi Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Natures Way Reishi Reishi Mushroom Supplements Products Offered 11.1.5 Natures Way Reishi Recent Development11.2 Solaray Reishi Mushroom 11.2.1 Solaray Reishi Mushroom Corporation Information 11.2.2 Solaray Reishi Mushroom Description, Business Overview and Total Revenue 11.2.3 Solaray Reishi Mushroom Sales, Revenue and Gross Margin (2015-2020) 11.2.4 Solaray Reishi Mushroom Reishi Mushroom Supplements Products Offered 11.2.5 Solaray Reishi Mushroom Recent Development11.3 Life Extension Reishi Extract 11.3.1 Life Extension Reishi Extract Corporation Information 11.3.2 Life Extension Reishi Extract Description, Business Overview and Total Revenue 11.3.3 Life Extension Reishi Extract Sales, Revenue and Gross Margin (2015-2020) 11.3.4 Life Extension Reishi Extract Reishi Mushroom Supplements Products Offered 11.3.5 Life Extension Reishi Extract Recent Development11.4 Host Defense Reishi 11.4.1 Host Defense Reishi Corporation Information 11.4.2 Host Defense Reishi Description, Business Overview and Total Revenue 11.4.3 Host Defense Reishi Sales, Revenue and Gross Margin (2015-2020) 11.4.4 Host Defense Reishi Reishi Mushroom Supplements Products Offered 11.4.5 Host Defense Reishi Recent Development11.5 Terrasoul Superfoods 11.5.1 Terrasoul Superfoods Corporation Information 11.5.2 Terrasoul Superfoods Description, Business Overview and Total Revenue 11.5.3 Terrasoul Superfoods Sales, Revenue and Gross Margin (2015-2020) 11.5.4 Terrasoul Superfoods Reishi Mushroom Supplements Products Offered 11.5.5 Terrasoul Superfoods Recent Development11.6 Swanson Reishi Mushroom 11.6.1 Swanson Reishi Mushroom Corporation Information 11.6.2 Swanson Reishi Mushroom Description, Business Overview and Total Revenue 11.6.3 Swanson Reishi Mushroom Sales, Revenue and Gross Margin (2015-2020) 11.6.4 Swanson Reishi Mushroom Reishi Mushroom Supplements Products Offered 11.6.5 Swanson Reishi Mushroom Recent Development11.7 Aloha Medicinals 11.7.1 Aloha Medicinals Corporation Information 11.7.2 Aloha Medicinals Description, Business Overview and Total Revenue 11.7.3 Aloha Medicinals Sales, Revenue and Gross Margin (2015-2020) 11.7.4 Aloha Medicinals Reishi Mushroom Supplements Products Offered 11.7.5 Aloha Medicinals Recent Development11.8 Mushroom Science 11.8.1 Mushroom Science Corporation Information 11.8.2 Mushroom Science Description, Business Overview and Total Revenue 11.8.3 Mushroom Science Sales, Revenue and Gross Margin (2015-2020) 11.8.4 Mushroom Science Reishi Mushroom Supplements Products Offered 11.8.5 Mushroom Science Recent Development11.9 Planetary Herbals 11.9.1 Planetary Herbals Corporation Information 11.9.2 Planetary Herbals Description, Business Overview and Total Revenue 11.9.3 Planetary Herbals Sales, Revenue and Gross Margin (2015-2020) 11.9.4 Planetary Herbals Reishi Mushroom Supplements Products Offered 11.9.5 Planetary Herbals Recent Development11.1 Natures Way Reishi 11.1.1 Natures Way Reishi Corporation Information 11.1.2 Natures Way Reishi Description, Business Overview and Total Revenue 11.1.3 Natures Way Reishi Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Natures Way Reishi Reishi Mushroom Supplements Products Offered 11.1.5 Natures Way Reishi Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 Reishi Mushroom Supplements Market Estimates and Projections by Region 12.1.1 Global Reishi Mushroom Supplements Sales Forecast by Regions 2021-2026 12.1.2 Global Reishi Mushroom Supplements Revenue Forecast by Regions 2021-202612.2 North America Reishi Mushroom Supplements Market Size Forecast (2021-2026) 12.2.1 North America: Reishi Mushroom Supplements Sales Forecast (2021-2026) 12.2.2 North America: Reishi Mushroom Supplements Revenue Forecast (2021-2026) 12.2.3 North America: Reishi Mushroom Supplements Market Size Forecast by Country (2021-2026)12.3 Europe Reishi Mushroom Supplements Market Size Forecast (2021-2026) 12.3.1 Europe: Reishi Mushroom Supplements Sales Forecast (2021-2026) 12.3.2 Europe: Reishi Mushroom Supplements Revenue Forecast (2021-2026) 12.3.3 Europe: Reishi Mushroom Supplements Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Reishi Mushroom Supplements Market Size Forecast (2021-2026) 12.4.1 Asia Pacific: Reishi Mushroom Supplements Sales Forecast (2021-2026) 12.4.2 Asia Pacific: Reishi Mushroom Supplements Revenue Forecast (2021-2026) 12.4.3 Asia Pacific: Reishi Mushroom Supplements Market Size Forecast by Region (2021-2026)12.5 Latin America Reishi Mushroom Supplements Market Size Forecast (2021-2026) 12.5.1 Latin America: Reishi Mushroom Supplements Sales Forecast (2021-2026) 12.5.2 Latin America: Reishi Mushroom Supplements Revenue Forecast (2021-2026) 12.5.3 Latin America: Reishi Mushroom Supplements Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Reishi Mushroom Supplements Market Size Forecast (2021-2026) 12.6.1 Middle East and Africa: Reishi Mushroom Supplements Sales Forecast (2021-2026) 12.6.2 Middle East and Africa: Reishi Mushroom Supplements Revenue Forecast (2021-2026) 12.6.3 Middle East and Africa: Reishi Mushroom Supplements Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Reishi Mushroom Supplements Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Reishi Mushroom Supplements Customers14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source16.2 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read more here:

Reishi Mushroom Supplements Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 - Weekly...